Edgar Filing: Weissman James B - Form 4

Form 4												
January 08, 2018	1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL		
		DINIL D		shington				000000	N OMB Number:	3235-0287		
Check this bo if no longer subject to Section 16. Form 4 or		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								Expires:January 31, 2005Estimated average burden hours per response0.5		
Form 5 obligations may continue <i>See</i> Instructio 1(b).	Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Resp	onses)											
1. Name and Address of Reporting Person <u>*</u> Weissman James B			2. Issuer Name and Ticker or Trading Symbol				ıg	5. Relationship of Reporting Person(s) to Issuer				
			Dicerna Pharmaceuticals Inc [DRNA]					(Check all applicable)				
(Last) C/O DICERNA PHARMACEU CAMBRIDGEI	TICALS, IN			of Earliest Tr Day/Year) 2018	ransaction			below)	ve title 00 below) of Business Office			
				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
CAMBRIDGE,	MA 02140							Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securi	ties Ac	equired, Disposed	of, or Beneficia	lly Owned		
	ransaction Date nth/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D)	Price	(Instr. 3 and 4)				
Reminder: Report of	on a separate lin	e for each cla	ass of sec	urities benef	ficially ow	ned dire	ectly or	indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Weissman James B - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative6. Date Exercisable and Expiration DateSecurities(Month/Day/Year)Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Employee Stock Option (Right to Buy)	\$ 9.3	01/04/2018		A	105,000	<u>(1)</u>	01/04/2028	Common Stock	105,00

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Weissman James B C/O DICERNA PHARMACEUTICALS 87 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140	5, INC.		Chief Business Officer				
Signatures							
/s/ John B. Green, attorney-in-fact	01/08/2018						
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in 48 monthly installments over the four-year period starting on the last day of January 2018, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.